[A17-59] Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) – Benefit assessment according to §35a Social Code Book (SGB) V
Last updated 15.02.2018
Commission awarded on 16.11.2017 by the Federal Joint Committee (G-BA).
Children's and adolescents' health
No study data; added benefit not proven in comparison with the appropriate comparator therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A13-25||Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)||Commission completed|